Abstract
We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10-21) weeks. The median overall survival was 70 (9-178) weeks and for responders it was 120 (22-178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients. © 2003 Cancer Research UK.
Original language | English |
---|---|
Pages (from-to) | 1335-1338 |
Number of pages | 3 |
Journal | British Journal of Cancer |
Volume | 88 |
Issue number | 9 |
DOIs | |
Publication status | Published - 6 May 2003 |
Keywords
- Docetaxel
- Hodgkin's disease
- Non-Hodgkin's lymphoma